Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04188548
Title A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company

Her2-receptor negative breast cancer

endometrial cancer

Her2-receptor positive breast cancer


Abemaciclib + LY3484356


Abemaciclib + LY3484356 + Trastuzumab

Abemaciclib + Anastrozole + LY3484356

Abemaciclib + Exemestane + LY3484356

Alpelisib + LY3484356

Everolimus + LY3484356

Abemaciclib + Letrozole + LY3484356

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | BEL

No variant requirements are available.